DNIB0600A Uses, Dosage, Side Effects and more
DNIB0600A is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
| Trade Name | DNIB0600A |
| Generic | Lifastuzumab vedotin |
| Lifastuzumab vedotin Other Names | DNIB0600A, Lifastuzumab vedotin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
